drugset
drugset / Trial / NCT00088231

PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP

NCT00088231 ↗

Phase 1/2 Completed 9 enrolled M.D. Anderson Cancer Center Novartis · collab
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to find the highest safe doses of PTK 787 (vatalanib) and Gleevec (imatinib mesylate) that can be given to treat Chronic Myelogenous Leukemia-Blastic Phase (CML-BP), Refractory Acute Myelogenous Leukemia (AML), or Agnogenic Myeloid Metaplasia (AMM). Another goal is to see how effective this combination treatment is.

Timeline

Start
2004-07
Primary completion
2006-10
Completion
2006-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Imatinib Small molecule 400 mg Oral
Subject Imatinib Small molecule 600 mg Oral
Subject vatalanib Small molecule 250 mg Oral

Indications

acute myeloid leukemia chronic myeloid leukemia myelofibrosis with myeloid metaplasia